Compare SMTI & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | BNTC |
|---|---|---|
| Founded | 1982 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.2M | 313.9M |
| IPO Year | 2008 | 2020 |
| Metric | SMTI | BNTC |
|---|---|---|
| Price | $35.05 | $8.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $35.00 | $24.33 |
| AVG Volume (30 Days) | 154.6K | ★ 176.7K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $14.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $8.52 |
| 52 Week High | $35.34 | $16.76 |
| Indicator | SMTI | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 63.39 | 29.23 |
| Support Level | $33.99 | N/A |
| Resistance Level | $35.34 | $13.49 |
| Average True Range (ATR) | 0.18 | 0.76 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 51.67 | 14.24 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.